

Title (en)
THERAPEUTIC USE OF G53135-05(FGF-20) IN RADIATION PROTECTION

Title (de)
THERAPEUTISCHE ANWENDUNG VON G53135-05(FGF-20) IM STRAHLENSCHUTZ

Title (fr)
USAGE THERAPEUTIQUE DE G53135-05 (FGF-20) EN PROTECTION CONTRE LES RAYONNEMENTS

Publication
EP 1660008 A2 20060531 (EN)

Application
EP 04751820 A 20040510

Priority
• US 2004014622 W 20040510
• US 46935303 P 20030509
• US 54430804 P 20040226

Abstract (en)
[origin: WO2005025489A2] The present invention relates to methods of preventing or treating one or more symptoms associated with radiation exposure. In particular, the present invention provides methods of preventing or treating one or more symptoms (e.g., gastrointestinal (GI) syndrome, hematopoietic (bone marrow) syndrome, and cerebrovascular (CNS) syndrome) associated with radiation exposure comprising administering to a subject in need thereof a composition comprising CG53135-05, a Fibroblast Growth Factor-20 (FGF-20) protein.

IPC 1-7
A61K 6/00

IPC 8 full level
A61K 38/18 (2006.01); **C07K 14/50** (2006.01)

IPC 8 main group level
A61K (2006.01)

CPC (source: EP)
A61K 38/1825 (2013.01); **A61P 1/02** (2017.12); **A61P 1/04** (2017.12); **A61P 1/08** (2017.12); **A61P 1/12** (2017.12); **A61P 3/02** (2017.12); **A61P 7/00** (2017.12); **A61P 7/04** (2017.12); **A61P 9/00** (2017.12); **A61P 11/00** (2017.12); **A61P 15/00** (2017.12); **A61P 17/02** (2017.12); **A61P 17/14** (2017.12); **A61P 25/00** (2017.12); **A61P 29/00** (2017.12); **A61P 39/02** (2017.12)

Citation (search report)
See references of WO 2005025489A2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2005025489 A2 20050324; **WO 2005025489 A3 20080904**; AU 2004271913 A1 20050324; CA 2531878 A1 20050324; EP 1660008 A2 20060531; JP 2007531702 A 20071108

DOCDB simple family (application)
US 2004014622 W 20040510; AU 2004271913 A 20040510; CA 2531878 A 20040510; EP 04751820 A 20040510; JP 2006526057 A 20040510